Live Feeds
● LIVE Updated 1h ago · 13 sources tracked

Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.

Moderna shares experienced significant volatility following an early data leak from the Phase 3 INTerpath-001 trial evaluating its personalized mRNA cancer vaccine, intismeran autogene, alongside Merck's Keytruda for melanoma. Although the trial successfully met its goal by reducing the risk of cancer recurrence or death by 42 percent compared to Keytruda alone, initial investor disappointment triggered a stock selloff and an 18 percent drop for Moderna. Meanwhile, other pharmaceutical competitors such as Amgen captured market enthusiasm by showcasing strong data for alternative oncology treatments during the ESMO Congress presentations.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ In a trial of 1,137 patients with surgically removed, high-risk stage 2B to 4 melanoma, intismeran autogene combined with Merck's Keytruda reduced the risk of recurrence or death by 42 percent versus Keytruda alone.
  • ✓ The combination treatment reduced the risk of distant metastasis or death by 38 percent.
  • ✓ At two years, 82.2 percent of patients receiving the combination therapy were alive and cancer-free, compared to 70 percent of patients treated with Keytruda alone.
  • ✓ Moderna shares fell 18 percent following the initial leak of the Phase 3 melanoma vaccine data.
🛡️ Source Corroboration: 13 independent reporting domains (95% confidence) ⏱ Read time: ~3 min

What changed

Analysts revised their initial skepticism after reviewing the full Phase 3 trial presentation at the ESMO Congress, warming to the vaccine data that had previously sparked a market selloff.

Live updates

  1. Moderna Cancer Vaccine Rally Stalls as Rivals Capture Attention

    Moderna shares experienced significant volatility following an early data leak from the Phase 3 INTerpath-001 trial evaluating its personalized mRNA cancer vaccine, intismeran autogene, alongside Merck's Keytruda for melanoma. Although the trial successfully met its goal by reducing the risk of cancer recurrence or death by 42 percent compared to Keytruda alone, initial investor disappointment triggered a stock selloff and an 18 percent drop for Moderna. Meanwhile, other pharmaceutical competitors such as Amgen captured market enthusiasm by showcasing strong data for alternative oncology treatments during the ESMO Congress presentations.

    Why it matters

    Personalized cancer vaccines represent a high-stakes frontier in biotechnology, aiming to train the body's immune system to target specific tumors based on individual genetic profiles. The partnership between Moderna and Merck is closely watched as a bellwether for the commercial and clinical viability of mRNA technology outside of infectious diseases. However, intense market scrutiny means even successful late-stage trial results can trigger sharp financial corrections if initial expectations or leaked figures fail to match hyper-specific investor forecasts.

    What is confirmed

    • In a trial of 1,137 patients with surgically removed, high-risk stage 2B to 4 melanoma, intismeran autogene combined with Merck's Keytruda reduced the risk of recurrence or death by 42 percent versus Keytruda alone.
    • The combination treatment reduced the risk of distant metastasis or death by 38 percent.
    • At two years, 82.2 percent of patients receiving the combination therapy were alive and cancer-free, compared to 70 percent of patients treated with Keytruda alone.
    • Moderna shares fell 18 percent following the initial leak of the Phase 3 melanoma vaccine data.

    Still unconfirmed

    • Another drugmaker reportedly stole the spotlight and captured market attention away from Moderna's cancer vaccine rally.

    What to watch next

    • Further clinical data presentations or trial readouts for mRNA cancer vaccines expanding beyond melanoma
    • Regulatory filings and progression toward commercialization for personalized cancer vaccines
    Sources used for this update (14)
    1. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
    2. NBC News — Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
    3. WSJ — Moderna Investors Should Brace for More Whiplash
    4. WIRED — New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
    5. Fierce Biotech — ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
    6. Barron's — Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
    7. Barron's — Moderna CEO Tells What the Market Got Wrong About its Cancer Vaccine
    8. Bloomberg.com — Moderna CEO Confident Cancer Vaccines Will Work Beyond Melanoma
    9. STAT — Cancer vaccines are finally here. How do we get them to patients?
    10. www.biospace.com — ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine ...
    11. tyriantrade.com — Moderna Cancer Vaccine Rally Stalls as Another Drugmaker ...
    12. www.talk.bio — Analysts warm to Merck–Moderna cancer vaccine after ESMO ...
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community